Recombinant obligate anaerobic Gram-positive bacteria
AssigneeTeikyo Heisei University
InventorsTakeshi Nishikawa, Yuichiro Taira, Ikuko Taira, Isao Ishida
Life of this patent
Estimating the term…
Abstract
An object of the present invention is to effectively induce cancer cell apoptosis using the anti-TRAIL-R1 antibody(ies) and the anti-TRAIL-R2 antibody(ies) and to reduce the toxicity imposed on normal cells. The present invention relates to recombinant obligate anaerobic Gram-positive bacteria that include a nucleic acid encoding a fusion protein having 3 or more anti-TRAIL-R1 single-chain antibodies and/or 3 or more anti-TRAIL-R2 single-chain antibodies, in an expressible state.
Claims8
A method of treating a tumor in a subject in need thereof, comprising administering recombinant bacteria of the genus Bifidobacterium to the subject in need thereof by an intravenous route;
- wherein the recombinant bacteria comprise a nucleic acid encoding a fusion protein, the fusion protein comprising a signal peptide and 3 or more anti-TRAIL-R1 single-chain antibodies and/or 3 or more anti-TRAIL-R2 single-chain antibodies, in an expressible state;
- and wherein the administered recombinant bacteria do not induce weight loss in the treated subject.
Dependencies are inferred from the claim text.